The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia

Current Opinion in Lipidology

Volumn 26, Issue 1, 2015, Pages 56-63

  Sacks, Frank M ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

apolipoprotein C III; apolipoprotein E; lipoproteins; metabolism

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNSATURATED FATTY ACID; VERY LOW DENSITY LIPOPROTEIN;

ANTIBODY AFFINITY; CARBOHYDRATE DIET; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOAFFINITY CHROMATOGRAPHY; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; METABOLIC REGULATION; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; DIET; ENZYMOLOGY; METABOLISM;

ANIMALS; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS E; DIET; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN LIPASE;

EID: 84920815242     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000146     Document Type: Review

References (51)

1. Beltz WF, Kesaniemi YA, Howard BV, Grundy SM. Development of an integrated model for analysis of the kinetics of apolipoprotein B in plasma very low density lipoproteins, intermediate density lipoproteins, and low density lipoproteins. J Clin Invest 1985; 76:575-585.
2. Kesaniemi YA, Beltz WJ, Grundy SM. Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease. J Clin Invest 1985; 76:586-595.
3. Teng B, Sniderman AD, Soutar AK, Thompson GR. Metabolic basis of hyperapobetalipoproteinemia. J Clin Invest 1986; 77:663-672.
4. Huff MW, Telford DE. Regulation of low density lipoprotein apoprotein B metabolism by lovastatin and cholestyramine in miniature pigs: effects on LDL composition and synthesis of LDL subfractions. Metabolism 1989; 38:256-264.
5. Fisher WR, Zech LA, Kilgore LL, Stacpoole PW. Metabolic pathways of apolipoprotein B in heterozygous familial hypercholesterolemia: studies with a [3H] leucine tracer. J Lipid Res 1991; 32:1823-1836.
6. Gaw A, Packard CJ, Lindsay GM, et al. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins. J Lipid Res 1995; 36:158-171.
7. Zheng CY, Khoo C, Ikewaki K, Sacks FM. Rapid turnover of apolipoprotein CIII-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res 2007; 48:1190-1203.
8. Mendivil C, Zheng C, Furtado J, et al. Metabolism of VLDL and LDL containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol 2010; 30:239-245.
9. Fisher WR, Zech LA, Stacpoole PW. ApoB metabolism in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1994; 14:501-510.
10. Zheng C, Furtado J, Khoo C, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense LDL phenotype. Circulation 2010; 121:1722-1734.
11. Campos H, Perlov D, Khoo C, Sacks FM. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res 2001; 42:1239-1249.
12. Khoo C, Campos H, Judge H, Sacks FM. Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and CIII. J Lipid Res 1999; 40:202-212.
13. Alaupovic P. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol 1996; 263:32-60.
14. Sacks FM, Brewer HB. Petar Alaupovic: the father of lipoprotein classification based on apolipoprotein composition. Arterioscler Thromb Vasc Biol 2014; 34:1111-1113.
15. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceriderich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997; 17:715-722.
16. Lee SJ, Campos H, Moye LA, Sacks FM. LDL particles containing apolipoprotein CIII are independent risk factors for coronary events in diabetic patients. Arterioscl Thromb Vasc Biol 2003; 23:853-858.
17. Mendivil CO, Rimm EB, Furtado J, et al. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 2011; 124:2065-2072.
18. Mendivil CO, Rimm EB, Furtado J, Sacks FM. Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease. J Am Heart Assoc 2013; 2:e000130.
19. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240:622-630.
20. Mahley RW, Huang Y. Atherogenic remnant lipoproteins: Role for proteoglycans in trapping, transferring, and internalising. J Clin Invest 2007; 117:94-98.
21. Windler E, Chao Y, Havel RJ. Regulation of the hepatic uptake of triglyceriderich lipoproteins in the rat: opposing effects of homologous apolipoprotein E and individual C apoproteins. J Biol Chem 1980; 255:8303-8307.
22. Yamada N, Shames DM, Stoudemire JB, Havel RJ. Metabolism of lipoproteins containing apolipoprotein B-100 in blood plasma of rabbits: Heterogeneity related to the presence of apolipoprotein E. Proc Natl Acad Sci 1986; 83:3479-3483.
23. Kashyap VS, Santamarina-Fojo S, Brown DR, et al. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J Clin Invest 1995; 96:1612-1620.
24. Pendse AA, Arbones-Mainar JM, Johnson LA, et al. Apolipoprotein E knockout and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J Lipid Res 2009; 50:S178-S182.
25. White CR, Garber DW, Anantharamaiah GM. Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review. J Lipid Res 2014; 55:2007-2021.
26. Hadattu SP, Nayyar G, Garber DW, et al. Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice. Atherosclerosis 2013; 227:58-64.
27. Tomiyasu K, Walsh BW, Ikewaki K, et al. Differential metabolism of human VLDL according to content of apolipoprotein E and CIII. Arterioscler Thromb Vasc Biol 2001; 21:1494-1500.
28. Lee SJ, Sacks FM. Effect of pravastatin on intermediate-density and lowdensity lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus. Am J Cardiol 2003; 92:121-124.
29. Zheng C, Khoo C, Furtado J, et al. Dietary monounsaturated fat activates pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III. Am J Clin Nutr 2008; 88:272-281.
30. Aalto-Setala K, Fisher EA, Chen X, et al. Mechanism of hypertriglyceridemia in human apo C-III transgenic mice: diminished VLDL fractional catabolic rate associated with increased apo C-III and reduced apo E on the particles. J Clin Invest 1992; 90:1889-1900.
31. Maeda N, Li H, Lee D, et al. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994; 269:23610-23616.
32. de Silva HV, Lauer SJ, Wang J, et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 1994; 269:2324-2335.
33. Demant T, Carlson LA, Holmquist L, et al. Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res 1988; 29:1603-1611.
34. Nicoll A, Lewis B. Evaluation of the roles of lipoprotein lipase and hepatic lipase in lipoprotein metabolism: in vivo and in vitro studies in man. Eur J Clin Invest 1980; 10:487-495.
35. Goldberg IJ, Le NA, Paterniti JR, et al. Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase on the cynomolgus monkey. J Clin Invest 1982; 70:1184-1192.
36. Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 1972; 46:375-382.
37. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apoliprotein C-III. J Clin Invest 1985; 75:384-390.
38. Liu H, Talmud PJ, Lins L, et al. Recombinant wild type and site-directed mutations of apolipoprotein C-III: lipid binding, displacement of ApoE, and inhibition of lipoprotein lipase. Biochemistry 2000; 39:9201-9212.
39. Larsson M, Vorrsjo E, Talmud P, et al. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem 2013; 288:33997-34008.
40. Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null nice. J Clin Invest 1997; 99:2672-2681.
41. Olin-Lewis K, Krauss RM, La Belle M, et al. ApoC-III content of apoBcontaining lipoproteins is associatedwith binding to the vascular proteoglycan biglycan. J Lipid Res 2002; 43:1969-1977.
42. Hiukka A, Stahlman M, Pettersson C, et al. ApoCIII-enriched LDL in type two diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes 2009; 58:2018-2026.
43. Jong MC, Rensen PC, Dahlmans VE, et al. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res 2001; 42:1578-1585.
44. Ginsberg HN, Le NA, Goldberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986; 78:1287-1295.
45. Cohn JS, Patterson BW, Uffelman KD, et al. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride inmale subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab 2004; 89:3949-3955.
46. Chan DC, Watts GF, Nguyen MN, Barrett PH. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B- 100 kinetics. Arterioscler Thromb Vasc Biol 2006; 26:590-596.
47. Sundaram M, Zhong S, Khalil MB, et al. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res 2010; 51:150-161.
48. Graham MJ, Lee RG, Bell TA, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Novelty and significance. Circ Res 2013; 112:1479-1490.
49. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003; 77:1146-1155.
50. Hu FB, Stampfer MJ, Manson JE, et al. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med 1997; 337:1491-1499.
51. Farvid JS, Ding M, Pan A, et al. Dietary linoleic acid and risk of coronary heart disease: a systematic review and meta-analysis of prospective cohort studies. Circulation 2014; 130:1568-1578.